Amphastar Pharmaceuticals Interest Expense 2011-2026 | AMPH

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Amphastar Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
23 K	4.08 M	-3.93 M	9.07 M	885 K	374 K	119 K	243 K	826 K	1.02 M	987 K	609 K	958 K	784 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
9.07 M	-3.93 M	1.15 M

Quarterly Interest Expense Amphastar Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
231 K	1.51 M	-2.23 M	-	-5.09 M	298 K	5.92 M	-	3.46 M	-1.52 M	398 K	-	566 K	397 K	355 K	-	527 K	86 K	104 K	-	175 K	35 K	76 K	-	22 K	24 K	30 K	-	124 K	100 K	18 K	-	264 K	237 K	191 K	-	281 K	305 K	384 K	-	232 K	210 K	341 K	-	504 K	476 K	180 K	-	195 K	237 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
5.92 M	-5.09 M	254 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
NextCure NXTC	1.77 M	$ 12.67	0.52 %	$ 354 M	USA
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Liquidia Corporation LQDA	2.34 M	$ 34.25	-0.38 %	$ 2.23 B	USA
Shattuck Labs STTK	-4 K	$ 5.02	6.13 %	$ 214 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
AbCellera Biologics ABCL	-2.71 M	$ 3.58	-1.38 %	$ 1.07 B	Canada
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
ADMA Biologics ADMA	-212 K	$ 15.57	-5.89 %	$ 3.71 B	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
ANI Pharmaceuticals ANIP	-4.03 M	$ 75.6	-1.22 %	$ 1.46 B	USA
Apellis Pharmaceuticals APLS	-133 K	$ 20.24	1.91 %	$ 2.55 B	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
Autolus Therapeutics plc AUTL	9.29 M	$ 1.5	-8.28 %	$ 383 M	Britain
AVEO Pharmaceuticals AVEO	1.6 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	-15.9 M	$ 159.87	-2.57 %	$ 7.95 B	USA
BridgeBio Pharma BBIO	43.1 M	$ 65.73	-1.22 %	$ 12.6 B	USA
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
BioLineRx Ltd. BLRX	9.07 M	$ 2.72	-3.31 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	15.3 M	$ 60.54	0.18 %	$ 11.6 B	USA
CymaBay Therapeutics CBAY	18.9 M	-	-	$ 3.45 B	USA
Codexis CDXS	-10.4 M	$ 1.25	16.2 %	$ 91.8 M	USA